Literature DB >> 11843298

Molecular genetics of type 2 von Willebrand disease.

Edith Fressinaud1, Claudine Mazurier, Dominique Meyer.   

Abstract

Type 2 von Willebrand disease (VWD) is characterized by a wide heterogeneity of functional and structural defects. These abnormalities' cause either defective von Willebrand factor (VWF)-dependent platelet function in subtypes 2A, 2B, and 2M or defective VWF-factor VIII (FVIII) binding in subtype 2N. The diagnoses of types 2A, 2B, and 2M VWD may be guided by the observation of disproportionately low levels of ristocetin cofactor activity or collagen-binding capacity relative to VWF antigen. The abnormal platelet-dependent function is often associated with the absence of high molecular weight (HMW) multimers (type 2A, type 2B), but the HMW multimers may also be present (type 2M, some type 2B), and supranormal multimers may exist ("Vicenza" variant). The observation of a low FVIII-to-VWF:Ag ratio is a hallmark of type 2N VWD. in which the FVIII levels depend on the severity of the FVIII-binding defect. Today, the identification of mutations in particular domains of the pre-pro-VWF is helpful in classifying these variants and providing further insight into the structure-function relationship and the biosynthesis of VWF. Thus, mutations in the D2 domain, involved in the multimerization process, are found in patients with type 2A, formerly named IIC VWD. Mutations located in the D' domain or in the N terminus of the D3 domain define type 2N VWD. Mutations in the D3 domain characterize Vicenza and IIE patients. Mutations in the A1 domain may modify the binding of VWF multimers to platelets, either increasing (type 2B) or decreasing (type 2M, 2A/2M) the affinity of VWF for platelets. In type 2A VWD, molecular abnormalities identified in the A2 domain, which contains a specific proteolytic site, are associated with alterations in folding, impairing VWF secretion or increasing its susceptibility to proteolysis. Finally, a mutation localized in the carboxy-terminus CK domain, which is crucial for the dimerization of the VWF subunit, has been identified in a rare subtype 2A, formerly named IID.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11843298     DOI: 10.1007/bf02981973

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  92 in total

1.  A new (K1518E) candidate mutation detected by universal heteroduplex generator analysis in a patient with type 2A (phenotype IIA) von Willebrand disease.

Authors:  M S Enayat; B D Theophilus; F G Hill; P E Rose; D Culpan; J Bidwell; G R Standen
Journal:  Thromb Haemost       Date:  1998-01       Impact factor: 5.249

2.  A type 2b von Willebrand disease mutation (Ile546-->Val) associated with an unusual phenotype.

Authors:  A B Federici; P M Mannucci; F Stabile; M T Canciani; N Di Rocco; S Miyata; J Ware; Z M Ruggeri
Journal:  Thromb Haemost       Date:  1997-09       Impact factor: 5.249

3.  Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695.

Authors:  V Siguret; A S Ribba; O Christophe; G Chérel; B Obert; C Rouault; T Nishikubo; D Meyer; J P Girma; G Piétu
Journal:  Thromb Haemost       Date:  1996-09       Impact factor: 5.249

4.  Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.

Authors:  C A Hillery; D J Mancuso; J Evan Sadler; J W Ponder; M A Jozwiak; P A Christopherson; J Cox Gill; J Paul Scott; R R Montgomery
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

5.  von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Authors:  L Holmberg; J A Dent; R Schneppenheim; U Budde; J Ware; Z M Ruggeri
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 6.  Diagnosis of von Willebrand disease.

Authors:  A B Federici
Journal:  Haemophilia       Date:  1998-07       Impact factor: 4.287

7.  A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

Authors:  J E Sadler
Journal:  Thromb Haemost       Date:  1994-04       Impact factor: 5.249

8.  Characterization of three mutations causing von Willebrand disease type IIA in five unrelated families.

Authors:  A Inbal; U Seligsohn; N Kornbrot; B Brenner; P Harrison; A Randi; I Rabinowitz; J E Sadler
Journal:  Thromb Haemost       Date:  1992-06-01       Impact factor: 5.249

9.  Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.

Authors:  A S Ribba; J Voorberg; D Meyer; H Pannekoek; G Pietu
Journal:  J Biol Chem       Date:  1992-11-15       Impact factor: 5.157

10.  Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.

Authors:  I Rabinowitz; A M Randi; K S Shindler; E A Tuley; P K Rustagi; J E Sadler
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

View more
  6 in total

1.  The calcium channel alpha2/delta1 subunit is involved in extracellular signalling.

Authors:  Kelly García; Thomas Nabhani; Jesús García
Journal:  J Physiol       Date:  2007-12-06       Impact factor: 5.182

2.  Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Authors:  Michelle Lavin; Sonia Aguila; Sonja Schneppenheim; Niall Dalton; Kenneth L Jones; Jamie M O'Sullivan; Niamh M O'Connell; Kevin Ryan; Barry White; Mary Byrne; Marie Rafferty; Mairead M Doyle; Margaret Nolan; Roger J S Preston; Ulrich Budde; Paula James; Jorge Di Paola; James S O'Donnell
Journal:  Blood       Date:  2017-09-15       Impact factor: 22.113

3.  Sequence and structure relationships within von Willebrand factor.

Authors:  Yan-Feng Zhou; Edward T Eng; Jieqing Zhu; Chafen Lu; Thomas Walz; Timothy A Springer
Journal:  Blood       Date:  2012-04-06       Impact factor: 22.113

4.  Platelet mediated TRAIL delivery for efficiently targeting circulating tumor cells.

Authors:  Nerymar Ortiz-Otero; Jocelyn R Marshall; Bradley W Lash; Michael R King
Journal:  Nanoscale Adv       Date:  2020-07-23

Review 5.  Acquired Von Willebrand Deficiency in Adults With Aortic Stenosis: A Systematic Review.

Authors:  Prasana Ramesh; Suthasenthuran Kanagalingam; Fnu Zargham Ul Haq; Nishok Victory Srinivasan; Aujala Irfan Khan; Ghadi D Mashat; Mohammad Hazique; Kokab Irfan Khan; Safeera Khan
Journal:  Cureus       Date:  2022-09-07

6.  What a polyclonal antibody sees in von Willebrand factor.

Authors:  Fen-Lai Tan; David Ginsburg
Journal:  Thromb Res       Date:  2007-07-05       Impact factor: 3.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.